Scott Livingston’s Post

Personal shoutout to the folks at Intra-Cellular Therapies who just announced a $132 per share buyout offer from Johnson & Johnson Livingston Securities played a small but important role as a part of the syndicate for the company's #directlisting - At the time, it was an innovative way to go public - proving that the traditional VC/IPO path isn't the only way to get listed on the Nasdaq. Important products & therapies came to market, patient investors were rewarded, and significant wealth was created, and this announcement is a vindication for #entrepreneurs and #financial professionals who try to think outside the box. #innovation #betterhealthcarecheaper #mentalhealth #wellness #neurotech #directlisting #publicmarkets #biotechmergers #intracellular #johnsonandjohnson NYSE Forbes BiotechNews & Life Sciences